+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Plasma Levels of Main Granulocyte Components during Hemodialysis: Effects of Immunosuppression

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Plasma levels of granulocyte lactoferrin, granulocyte myeloperoxidase and granulocyte elastase in complex with α<sub>r</sub>proteinase inhibitor were investigated during hemodialysis in oliguric patients following cadaveric renal transplantation (CRT). The results were compared with those of patients undergoing regular hemodialysis treatment (RDT) using different membrane materials. In RDT patients, plasma lactoferrin levels increased from 61.9 ± 10.2 to 417.9 ± 96.7 using dialyzers made of cuprophane. Dialyzers made of polymethyl methacrylate induced an increase of lactoferrin from 166.6 ± 28.5 to 712.5 ± 165.9 and dialyzers made of polyacrylonitrile an increase from 122.6 ± 23.5 to 647.7 ± 203.6 ng/ml. In CRT patients, in contrast, plasma lactoferrin levels increased from 49.1 ± 10.9 to 199.6 ± 45.9 (cuprophane), from 30.1 ± 6.9 to 252.5 ± 46.9 (polymethyl methacrylate), and from 43.3 ± 9.1 to 174.2 ± 39.3 ng/ml (polyacrylonitrile). On the other hand, the plasma levels’ of myeloperoxidase and elastase in complex with αi-proteinase inhibitor increased comparably in both groups of patients. Our data suggest that immunosuppression might prevent degranulation of specific granules independently of the used dialyzer membrane material, whereas no effect was observed on two main components of azurophilic granules.

          Related collections

          Author and article information

          S. Karger AG
          05 December 2008
          : 46
          : 2
          : 161-166
          Division of Nephrology, Department of Medicine, and Department of Surgery, University of Freiburg, FRG
          184333 Nephron 1987;46:161–166
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article